Nonalcoholic Steatohepatitis (NASH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Nonalcoholic Steatohepatitis (NASH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Nonalcoholic Steatohepatitis (NASH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Nonalcoholic Steatohepatitis (NASH) Therapeutics market. The report identifies the key trends shaping and driving the global Nonalcoholic Steatohepatitis (NASH) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Nonalcoholic Steatohepatitis (NASH) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Nonalcoholic Steatohepatitis (NASH) Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Nonalcoholic Steatohepatitis (NASH) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Nonalcoholic Steatohepatitis (NASH) Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Nonalcoholic Steatohepatitis (NASH) Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Nonalcoholic Steatohepatitis (NASH) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Nonalcoholic Steatohepatitis (NASH) Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Nonalcoholic Steatohepatitis (NASH) Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Nonalcoholic Steatohepatitis (NASH) Therapeutics market landscape? - Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 NONALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS - INTRODUCTION

2.1 Disease Overview
2.2 Epidemiology
  2.2.1 Quality of Life Parameters
  2.2.2 Mortality
2.3 Etiology and Pathophysiology
2.4 Signs and Symptoms
2.5 Diagnosis
  2.5.1 Ultrasonography
  2.5.2 Computed Tomography
  2.5.3 Magnetic Resonance Imaging
  2.5.4 Liver function tests
  2.5.5 Liver Biopsy
  2.5.6 Trends in Diagnosis of NASH
2.6 Treatment and Management Options
  2.6.1 Trends in the Treatment of NASH
  2.6.2 Prevention
2.7 GlobalData Pipeline Report Guidance

3 NASH THERAPEUTICS - MARKET CHARACTERIZATION

3.1 Overview
3.2 NASH Therapeutics Market Size (2005–2010) – Global
3.3 NASH Therapeutics Market Forecast (2010–2018) – Global
3.4 NASH Therapeutics Market Size (2005–2010) – The US
3.5 NASH Therapeutics Market Forecast (2010–2018) – The US
3.6 NASH Therapeutics Market Size (2005–2010) – France
3.7 NASH Therapeutics Market Forecast (2010–2018) – France
3.8 NASH Therapeutics Market Size (2005–2010) – Germany
3.9 NASH Therapeutics Market Forecast (2010–2018) – Germany
3.10 NASH Therapeutics Market Size (2005–2010) – Italy
3.11 NASH Therapeutics Market Forecast (2010–2018) – Italy
3.12 NASH Therapeutics Market Size (2005–2010) – Spain
3.13 NASH Therapeutics Market Forecast (2010–2018) – Spain
3.14 NASH Therapeutics Market Size (2005–2010) – The UK
3.15 NASH Therapeutics Market Forecast (2010–2018) – The UK
3.16 NASH Therapeutics Market Size (2005–2010) – Japan
3.17 NASH Therapeutics Market Forecast (2010–2018) – Japan
3.18 Drivers and Barriers for the NASH Therapeutics Market
  3.18.1 Drivers for the NASH Therapeutics Market
  3.18.2 Barriers for the NASH Therapeutics Market
3.19 Opportunity and Unmet Need Analysis
3.20 Key Takeaway

4 NASH THERAPEUTICS - COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Off-Label Marketed Products in the NASH Market
  4.3.1 Antioxidants
  4.3.2 Anti-Diabetes Medications
  4.3.3 Anti-Obesity Medications
  4.3.4 Antihyperlipidemics
4.4 Key Takeaway

5 NASH THERAPEUTICS - PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 NASH Therapeutics Pipeline – Pipeline by Phases of Development
  5.3.1 NASH Therapeutics – Phase III Pipeline
  5.3.2 NASH Therapeutics – Phase II Pipeline
  5.3.3 NASH Therapeutics – Phase I Pipeline
  5.3.4 NASH Market – Discovery and Pre-Clinical Pipeline
5.4 NASH Therapeutics Market – Pipeline by Mechanism of Action
5.5 Technology Trends Analytic Framework
5.6 NASH Therapeutics – Promising Drugs Under Development
5.7 Molecule Profile for Promising Drugs Under Development
  5.7.1 GS 9450 (LB84451)
  5.7.2 DR Cysteamine (Delayed Release Cysteamine Bitartrate)
  5.7.3 EGS21 (β-glucosylceramide formulation)
  5.7.4 Anti-CD3 Monoclonal Antibody (aCD3 MAb, OKT3)
5.8 Key Takeaway

6 NASH THERAPEUTICS - CLINICAL TRIALS MAPPING

6.1 Clinical Trials by Region/Country (the US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in NASH Therapeutics Clinical Trials

7 STRATEGIC ASSESSMENT

7.1 Key Events Impacting the Future Market
7.2 NASH Therapeutics - Implications for Future Market Competition

8 NASH THERAPEUTICS - FUTURE PLAYERS

8.1 Introduction
8.2 Company Profiles
  8.2.1 Raptor Pharmaceutical Corp.
  8.2.2 Gilead Sciences, Inc.
  8.2.3 Enzo Biochem, Inc.

9 NASH THERAPEUTICS - APPENDIX

9.1 Market Definitions
9.2 Abbreviations
9.3 Methodology
  9.3.1 Coverage
  9.3.2 Secondary Research
  9.3.3 Forecasting
  9.3.4 Primary Research
  9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Bibliography

LIST OF TABLES

Table 1: NASH Therapeutics Market, Global, Prevalence of Liver Abnormalities Among Obese, Diabetic and General Population (%)
Table 2: NASH Therapeutics Market, Global, Prevalence of Parameters (%) of Metabolic Syndromes in Nonalcoholic Steatohepatitis
Table 3: Grading and Staging of NASH
Table 4: Therapeutic Options for the Treatment of NASH
Table 5: NASH Therapeutics Market, Global, Revenue ($m), 2005–2010
Table 6: NASH Therapeutics Market, Global, Forecast ($m), 2010–2018
Table 7: NASH Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 8: NASH Therapeutics Market, The US, Forecast ($m), 2010–2018
Table 9: NASH Therapeutics Market, France, Revenue ($m), 2005–2010
Table 10: NASH Therapeutics Market, France, Forecast ($m), 2010–2018
Table 11: NASH Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 12: NASH Therapeutics Market, Germany, Forecast ($m), 2010–2018
Table 13: NASH Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 14: NASH Therapeutics Market, Italy, Forecast ($m), 2010–2018
Table 15: NASH Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 16: NASH Therapeutics Market, Spain, Forecast ($m), 2010–2018
Table 17: NASH Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 18: NASH Therapeutics Market, The UK, Forecast ($m), 2010–2018
Table 19: NASH Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 20: NASH Therapeutics Market, Japan, Forecast ($m), 2010–2018
Table 21: NASH Therapeutics, Phase III Pipeline, 2011
Table 22: NASH Therapeutics, Phase II Pipeline, 2011
Table 23: NASH Therapeutics, Phase I Pipeline, 2011
Table 24: NASH Therapeutics, Discovery and Pre-Clinical Pipeline, 2011
Table 25: NASH Therapeutics – Most Promising Drugs Under Development, 2011
Table 26: NASH Therapeutics, Clinical Trials by Country, 2011
Table 27: NASH Therapeutics, Clinical Trials by Phase, 2011
Table 28: NASH Therapeutics, Clinical Trials by Status of Development, 2011
Table 29: NASH Therapeutics, Prominent Sponsors, 2011
Table 30: NASH Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 31: Raptor Pharmaceutical Corp., Liver Disease Management, Pipeline, 2011
Table 32: Raptor Pharmaceutical Corp., Deals, 2009–2011
Table 33: Gilead Sciences, Inc., Liver Disease Management, Pipeline, 2011
Table 34: Gilead Sciences, Inc., Deals, 2009-2011
Table 35: Enzo Biochem, Inc., Liver Disease Management, Pipeline, 2011
Table 36: Enzo Biochem, Inc., Deals, 2009-2011

LIST OF FIGURES

Figure 1: Spectrum of NAFLD
Figure 2: Two-Hit Hypothesis of NASH Pathogenesis
Figure 3: Mechanisms Leading to Liver Steatosis
Figure 4: Factors Contributing to the Development of NASH from a Steatotic Liver
Figure 5: Treatment Targets for NASH
Figure 6: NASH Therapeutics – Referral Pathway
Figure 7: NASH Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 8: NASH Therapeutics Market, Global, Forecast ($m), 2010–2018
Figure 9: NASH Therapeutics Market, The US, Revenue ($m), 2005–2010
Figure 10: NASH Therapeutics Market, The US, Forecast ($m), 2010–2018
Figure 11: NASH Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 12: NASH Therapeutics Market, France, Forecast ($m), 2010–2018
Figure 13: NASH Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 14: NASH Therapeutics Market, Germany, Forecast ($m), 2010–2018
Figure 15: NASH Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 16: NASH Therapeutics Market, Italy, Forecast ($m), 2010–2018
Figure 17: NASH Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 18: NASH Therapeutics Market, Spain, Forecast ($m), 2010–2018
Figure 19: NASH Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 20: NASH Therapeutics Market, The UK, Forecast ($m), 2010–2018
Figure 21: NASH Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 22: NASH Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 23: Opportunity and Unmet Need in the NASH Therapeutics Market, 2010
Figure 24: NASH Therapeutics, Strategic Competitor Assessment, 2010
Figure 25: NASH Therapeutics – Pipeline by Phase of Development, 2011
Figure 26: NASH Therapeutics, Pipeline by Mechanism of Action (%), 2011
Figure 27: NASH Therapeutics, Technology Trends Analytics Framework, 2011
Figure 28: NASH Therapeutics, Technology Trends Analytics Framework, Description, 2011
Figure 29: NASH Therapeutics, Clinical Trials by Country, 2011
Figure 30: NASH Therapeutics, Clinical Trials by Phase (%), 2011
Figure 31: NASH Therapeutics, Clinical Trials by Status of Development (%), 2011
Figure 32: NASH Therapeutics, Overall Sponsors (%), 2011
Figure 33: NASH Therapeutics, Prominent Sponsors (%), 2011
Figure 34: NASH Therapeutics, Top Companies Participating in Clinical Trials, 2011
Figure 35: NASH Therapeutics Market, Drivers and Restraints, 2011
Figure 36: Implications for Future Market Competition in the NASH Market, 2011
Figure 37: NASH Therapeutics Market, Pipeline by Company, 2011

COMPANIES MENTIONED

Raptor Pharmaceutical Corp.
Gilead Sciences, Inc.
Enzo Biochem, Inc. Skip to top